Mifepristone followed by high-dose oxytocin drip for second-trimester abortion: A randomized, double-blind, placebo-controlled, pilot study

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 54, Issue 8, 2009, Pages 511-516

  Ben Meir, Assaf ^a   Erez, Yair ^a   Feigenberg, Tomer ^a   Hamani, Yaron ^a   Laufer, Neri ^a   Rojansky, Nathan ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

Induced abortion; Mifepristone; Missed abortion; Oxytocin

Indexed keywords

MIFEPRISTONE; OXYTOCIN; PLACEBO; ABORTIVE AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; GESTATIONAL AGE; HUMAN; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SECOND TRIMESTER ABORTION; DRUG COMBINATION; INDUCED ABORTION; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MISSED ABORTION; ORAL DRUG ADMINISTRATION; PREGNANCY; SECOND TRIMESTER PREGNANCY;

ABORTIFACIENT AGENTS; ABORTION, INDUCED; ABORTION, MISSED; ADMINISTRATION, ORAL; ADULT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIERS ESTIMATE; MIFEPRISTONE; OXYTOCIN; PILOT PROJECTS; PLACEBOS; PREGNANCY; PREGNANCY TRIMESTER, SECOND; YOUNG ADULT;

EID: 70350490806     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Elam-Evans LD, Strauss LT, Herndon J, et al: Abortion surveillance-United States, 2000. MMWR CDC Surveill Summ 2003;52:1-32
2. Stubblefield PG, Carr-Ellis S, Borgatta L: Methods for induced abortion. Obstet Gynecol 2004;104:174-185
3. Yapar EG, Senoz S, Urkutur M, et al: Second trimester pregnancy termination including fetal death: Comparison of five different methods. Eur J Obstet Gynecol Reprod Biol 1996;69:97-102
4. Bygdeman M, Swahn ML: Progesterone receptor blockage: Effect on uterine contractility and early pregnancy. Contraception 1985;32:45-51
5. Bygdeman M, Swahn ML, Gemzell-Danielsson Gottlieb C: The use of progesterone antagonists in combination with prostaglandin for termination of pregnancy. Hum Reprod 1994;9:121-125
6. Schreiber C, Creinin M: Mifepristone in abortion care. Semin Reprod Med 2005;23:82-91
7. Neilson JP: Mifepristone for induction of labour (Cochrane Review). In Oxford, the Cochrane Library, issue 4, 2000, CD002865
8. Ashok PW, Templeton A, Wagaarachchi PT: Midtrimester medical termination of pregnancy: A review of 1002 consecutive cases. Contraception 2004;69:51-58
9. Loudon JD: The use of high concentration oxytocin intravenous drips in the management of missed abortion. J Obstet Gynaecol Br Emp 1959;66:277-281
10. Kapp N, Borgatta L, Stubblefield P, et al: Mifepristone in second-trimester medical abortion: A randomized controlled trial. Obstet Gynecol 2007;110:1304-1310
11. Winkler CL, Gray SE, Hauth JC, et al: Mid-second-trimester labor induction: Concentrated oxytocin compared with prostaglandin E2 vaginal suppositories. Obstet Gynecol 1991;77:297-300
12. Owen J, Hauth JC, Winkler CL, et al: Midtrimester pregnancy termination: A randomized trial of prostaglandin E2 versus concentrated oxytocin. Am J Obstet Gynecol 1992;167:1112-1116
13. Grimes DA, Smith MS, Witham AD: Mifepristone and misoprostol versus dilation and evacuation for midtrimester abortion: A pilot randomised controlled trial. Br J Obstet Gynaecol 2004;111:148-153
14. Norman JE: Uterine rupture during therapeutic abortion in the second trimester using mifepristone and prostaglandin. Br J Obstet Gynaecol 1995;102:332-333
15. Phillips K, Berry C, Mathers AM: Uterine rupture during second trimester termination of pregnancy using mifepristone and a prostaglandin. Eur J Obstet Gynecol Reprod Biol 1996;65:175-176
16. Sanchez-Ramos L, Kaunitz AM: Uterine rupture associated with the use of prostaglandin E1 in patients with previous cesarean delivery. Am J Obstet Gynecol 2000;182:990-991
17. Bagga R, Chaudhary N, Karla J: Rupture in an unscarred uterus during second trimester pregnancy termination with mifepristone and misoprostol. Int J Gynaecol Obstet 2004;87:42-43
18. Garfield RE, Blennerhasset MG, Miller SM: Control of myometrial contractility: Role and regulation of gap junctions. Oxf Rev Reprod Biol 1988;10:436-490
19. Swahn ML, Bygdeman M: The effect of the antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandin and oxytocin. Br J Obstet Gynaecol 1988;95:126-134
20. Hill NC, Selinger M, Ferguson J, et al: The physiological and clinical effects of progesterone inhibition with mifepristone (RU 486) in the second trimester. Br J Obstet Gynaecol 1990;97:487-492
21. Chwalisz K, Fahrenholz F, Hackenberg M, et al: The progesterone antagonist onapristone increases the effectiveness of oxytocin to produce delivery without changing the myometrial oxytocin receptor concentrations. Am J Obstet Gynecol 1991;165:1760-1770
22. Fang X, Wong S, Mitchell BF: Effects of RU486 on estrogen, progesterone, oxytocin, and their receptors in the rat uterus during late gestation. Endocrinology 1997;138:2763-2768